- Home
- INSM vs CAVA Comparison
INSM vs CAVA Comparison
Compare INSM & CAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- CAVA
- Stock Information
- Founded
- INSM 1988
- CAVA 2006
- Country
- INSM United States
- CAVA United States
- Employees
- INSM N/A
- CAVA N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- CAVA Restaurants
- Sector
- INSM Health Care
- CAVA Consumer Discretionary
- Exchange
- INSM Nasdaq
- CAVA Nasdaq
- Market Cap
- INSM 12.6B
- CAVA 10.9B
- IPO Year
- INSM 2000
- CAVA 2023
- Fundamental
- Price
- INSM $65.08
- CAVA $93.93
- Analyst Decision
- INSM Strong Buy
- CAVA Buy
- Analyst Count
- INSM 16
- CAVA 14
- Target Price
- INSM $95.36
- CAVA $123.00
- AVG Volume (30 Days)
- INSM 2.5M
- CAVA 2.3M
- Earning Date
- INSM 05-08-2025
- CAVA 05-15-2025
- Dividend Yield
- INSM N/A
- CAVA N/A
- EPS Growth
- INSM N/A
- CAVA 423.81
- EPS
- INSM N/A
- CAVA 1.10
- Revenue
- INSM $381,030,000.00
- CAVA $963,713,000.00
- Revenue This Year
- INSM $30.36
- CAVA $25.45
- Revenue Next Year
- INSM $115.55
- CAVA $21.09
- P/E Ratio
- INSM N/A
- CAVA $85.55
- Revenue Growth
- INSM 20.77
- CAVA 32.25
- 52 Week Low
- INSM $21.92
- CAVA $70.00
- 52 Week High
- INSM $84.91
- CAVA $172.43
- Technical
- Relative Strength Index (RSI)
- INSM 35.80
- CAVA 54.61
- Support Level
- INSM $63.81
- CAVA $90.75
- Resistance Level
- INSM $73.39
- CAVA $96.75
- Average True Range (ATR)
- INSM 2.53
- CAVA 3.42
- MACD
- INSM -0.38
- CAVA 0.66
- Stochastic Oscillator
- INSM 13.26
- CAVA 77.49
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.